Want to see INBS full AI Analyst Report?
INBS Stock Chart & Stats
$1.75
-$0.06(-3.31%)
At close: 4:00 PM EDT
$1.75
-$0.06(-3.31%)
Day’s Range― - ―
52-Week Range$1.52 - $24.90
Previous CloseN/A
Volume62.24K
Average Volume (3M)67.31K
Market Cap
$4.90M
Enterprise Value$0.11
Total Cash (Recent Filing)$6.86M
Total Debt (Recent Filing)$1.85M
Price to Earnings (P/E)―
Beta1.35
Next Earnings
Nov 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-12.52
Shares Outstanding2,391,846
10 Day Avg. Volume140,200
30 Day Avg. Volume67,309
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)3.03
Price to Sales (P/S)2.97
P/FCF Ratio-0.92
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-93.6
Revenue Forecast (FY)$14.65M
Bulls Say, Bears Say
Bulls Say
Recurring Consumables RevenueINBS’s business model centers on single-use test cartridges tied to portable readers, creating a recurring revenue stream that can deliver predictable, high-margin consumable sales over time. Durable consumable demand supports unit economics and makes revenue more repeatable as deployments scale.
Regulatory Progress And Manufacturing Cost PlanCompletion of cybersecurity remediation and clinical/precision studies materially reduces FDA execution risk, while the manufacturing partnership promises over 40% production cost savings and ~20ppt gross margin uplift. Together these structural moves improve scale economics and the odds of a viable U.S. commercial launch.
Early Top-line MomentumTTM revenue growth and reported improvement indicate increasing adoption of the fingerprint screening system. Sustained top-line momentum can help absorb fixed costs, improve operating leverage, and create a pathway to narrower losses if maintained through commercial execution and margin enhancements.
Bears Say
Sustained Cash BurnLarge negative operating and free cash flows are a persistent structural constraint, forcing reliance on external funding. Continued cash burn limits investment in commercialization and inventory, increases financing pressure, and raises the probability of dilution or interrupted growth absent rapid path to positive cash generation.
Deep Negative ProfitabilitySeverely negative net margins and falling gross margin show the current cost structure and pricing mix are not sustainable. Without material margin recovery from manufacturing savings or scale, persistent losses will erode equity and make durable profitability unlikely in the medium term.
Reliance On Equity Funding And DilutionFrequent equity transactions and advisory-compensation in stock indicate ongoing dependence on capital markets. This raises dilution risk for existing shareholders, can depress per-share economics over time, and signals persistent funding needs until the business reaches self-sustaining cash flow.
Intelligent Bio Solutions News
INBS FAQ
What was Intelligent Bio Solutions’s price range in the past 12 months?
Intelligent Bio Solutions lowest stock price was $1.52 and its highest was $24.90 in the past 12 months.
What is Intelligent Bio Solutions’s market cap?
Intelligent Bio Solutions’s market cap is $4.90M.
When is Intelligent Bio Solutions’s upcoming earnings report date?
Intelligent Bio Solutions’s upcoming earnings report date is Nov 05, 2026 which is in 83 days.
How were Intelligent Bio Solutions’s earnings last quarter?
Intelligent Bio Solutions released its earnings results on May 13, 2026. The company reported -$1.8 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Intelligent Bio Solutions overvalued?
According to Wall Street analysts Intelligent Bio Solutions’s price is currently Overvalued.
Does Intelligent Bio Solutions pay dividends?
Intelligent Bio Solutions does not currently pay dividends.
What is Intelligent Bio Solutions’s EPS estimate?
Intelligent Bio Solutions’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Intelligent Bio Solutions have?
Intelligent Bio Solutions has 2,391,846 shares outstanding.
What happened to Intelligent Bio Solutions’s price movement after its last earnings report?
Intelligent Bio Solutions reported an EPS of -$1.8 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 25.472%.
Which hedge fund is a major shareholder of Intelligent Bio Solutions?
Currently, no hedge funds are holding shares in INBS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Intelligent Bio Solutions
Intelligent Bio Solutions Inc. operates as a life sciences firm focused on developing non-invasive, real-time monitoring and diagnostic solutions for both patients and their primary healthcare providers. A notable product in its portfolio is the Saliva Glucose Biosensor, an organic thin-film transistor designed to precisely measure glucose levels in saliva for effective diabetes management. Beyond this, the company is actively developing a SARS-CoV-2 Biosensor, intended to serve as a supplementary diagnostic tool to existing RNA virus detection methods. It also maintains a broad biosensor platform that encompasses diverse diagnostic modalities, including biochemistry, immunology, tumor marker identification, hormone analysis, and nucleic acid diagnostics. Incorporated in 2016 and based in New York, New York, the company was formerly known as GBS Inc. before adopting its current name in October 2022. Intelligent Bio Solutions Inc. operates as a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
Technical Analysis
Ownership Overview
3.78% Insiders
0.63% Mutual Funds
7.03% Other Institutional Investors
88.32% Public Companies and
Individual Investors